Gallstones are the side effect that sounds alarming, turns out to be uncommon, and then happens to someone you know — at which point the statistics stop being reassuring.
They deserve a clear-eyed treatment, because the risk is real, the mechanism is well understood, and unlike most things on the side-effect list there is something practical you can do about it.
The numbers, in proportion
The best single source is a 2022 meta-analysis in JAMA Internal Medicine pooling 76 randomised trials. It found GLP-1 receptor agonists associated with a relative risk of about 1.37 for gallbladder or biliary disease.
A 37 percent increase sounds substantial. Applied to an uncommon event it is less dramatic than it reads: in STEP 1, cholelithiasis was reported in 2.6 percent of people on semaglutide against 1.2 percent on placebo. Roughly one additional case per seventy people treated.
The same analysis found the risk rose with higher doses, longer treatment, and — importantly — was greater in trials using these drugs for weight loss than for diabetes. That gradient is the clue to the mechanism.
1.37
Relative risk of gallbladder or biliary disease with GLP-1 agonists
JAMA Intern Med, 2022
2.6% vs 1.2%
Gallstones on semaglutide versus placebo in STEP 1
NEJM, 2021
~1 in 70
Approximate number needed to harm for one additional case
Why weight loss does this
Bile is a solution of cholesterol held in suspension by bile salts and phospholipids. It is stable within a fairly narrow range and readily forms crystals outside it.
When you mobilise stored fat quickly, the liver secretes more cholesterol into bile. The solution moves toward supersaturation.
Simultaneously, you are eating less. The gallbladder contracts in response to cholecystokinin, released mainly when fat reaches the small intestine. Eat little, and eat little fat in particular, and the gallbladder sits full of increasingly concentrated bile for long stretches.
Supersaturated bile plus stasis is the recipe. It is precisely why gallstones have always been common after bariatric surgery and on very-low-calorie diets, decades before anyone injected a GLP-1.
What an attack actually feels like
Biliary colic is not a vague ache. People who have had one do not usually wonder whether they had one.
The pattern: severe, steady pain in the upper right abdomen or under the breastbone, often beginning one to two hours after a fatty meal and frequently at night. It commonly radiates to the right shoulder blade. Nausea and sweating are usual. It builds over a few minutes, plateaus, and lasts anywhere from half an hour to several hours.
The confusion on a GLP-1 is obvious — nausea and upper abdominal discomfort after a fatty meal describes an ordinary Tuesday for a lot of people in month two. The distinguishing features are the severity, the steadiness, and the radiation to the back or shoulder.
What reduces the risk
Do not chase speed. The faster the loss, the higher the risk — this is one of the clearest arguments against the “lose as much as possible before insurance runs out” strategy, and against escalating doses ahead of schedule.
Keep some fat in your meals. This is the counterintuitive one. Fat is the signal that makes the gallbladder empty. A person on a GLP-1 who has also gone very low fat has arranged for their gallbladder to sit still for weeks. Regular meals containing some fat — olive oil, nuts, oily fish, whole eggs — keep it cycling.
Eat at regular intervals. Long gaps compound stasis. Three modest meals beat one late one, for this reason among several others.
Do not skip meals entirely. Appetite suppression makes it easy to go a day on coffee. The gallbladder notices.
There is a pharmacological option in specific circumstances: ursodeoxycholic acid reduces stone formation during rapid weight loss and is used routinely after bariatric surgery. It is not standard practice for GLP-1 users, but it is a reasonable conversation if you have had stones before or are losing weight very quickly.
The advice that protects your gallbladder is the same advice that protects your muscle: slower, steadier, and with actual meals in it.
If you already have gallstones
Known, silent stones are not automatically a reason to avoid these drugs — most stones never cause symptoms. It does change the risk calculation, and it is worth your prescriber knowing.
If you have had a cholecystectomy, you cannot get gallstones again and this entire category of risk is off your list. Some people do get looser stools with fatty meals afterwards, which a GLP-1 can compound.
Keeping it in proportion
One additional case per seventy people, against a drug class that produces fifteen to twenty percent weight loss and, in the cardiovascular outcome data, a measurable reduction in heart attacks and strokes.
That is a trade most people would take knowingly. The point of knowing about it is not to be frightened — it is to lose the weight at a rate your biliary system can keep up with, and to recognise the pain if it comes.